<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177553</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#105690</org_study_id>
    <nct_id>NCT01177553</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery</brief_title>
  <official_title>Randomized Clinical Trial: Expectant Management vs. Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation And Absent or Reverse Diastolic Flow in the Umbilical Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrauterine growth retardation (IUGR) occurs in approximately 3 to 10% of singleton
      pregnancies, in 9.1% of all twins and 9.9% of monochorionic twins. IUGR in monochorionic
      twins typically affects only one of the fetuses (selective IUGR or SIUGR). Spontaneous demise
      of the SIUGR twin can occur, and may result in concomitant demise (up to 40% risk) or severe
      neurologic handicap (up to 30% risk) of the other twin. These complications result from
      exsanguination of the appropriately grown (AGA) twin into the demised SIUGR twin through
      placental vascular communications.

      Because the adverse effects to the AGA twin of the spontaneous demise of the SIUGR twin are
      mediated through placental vascular anastomoses, we have proposed obliterating such
      anastomoses via endoscopic fetal surgery. We have developed a technique that allows us to
      identify the vascular anastomoses present in monochorionic placentas. Briefly, deep AV
      communications are identified on the surface of the placenta by noting that the terminal end
      of the artery of one of the fetuses does not have a corresponding returning vein to the same
      fetus. We have speculated that the separation of the circulations may be of benefit in
      monochorionic twins affected by SIUGR by preventing the adverse effects that may result from
      the spontaneous demise of the IUGR twin. Our goal is to evaluate with a randomized clinical
      trial the outcome of SIUGR managed either expectantly or with SLPCV.

      Study procedures will begin with confirmation of the diagnosis and screening criteria at the
      Qualified Clinical Center. The patient will sign the appropriate consents and then be
      randomized to her treatment group. Enrollment data will be submitted to the research
      coordinator in Coordinating Center in Tampa. Expectant management patients will be treated by
      the referring physicians. Laser patients will be treated at Coordinating Center in Tampa
      General Hospital or qualified laser center. They may return to the referring center for
      follow-up. After delivery, outcome data will be sent to the research coordinator in
      Coordinating Center in Tampa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Effects of surgery or expectant management on postnatal neurological morbidity of the AGA baby. The primary comparison will be between SLPCV (selective laser photocoagulation of communicating vessels) and expectant management.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal/Neonatal/Infant Survival of the AGA Fetus 6 Months After Birth, Comparing the SLPCV (Selective Laser Photocoagulation of Communicating Vessels) and Expectant Management Groups.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Intrauterine Growth Retardation</condition>
  <arm_group>
    <arm_group_label>Surgery Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.
Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expectant Management Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>selective laser photocoagulation of communicating vessels</intervention_name>
    <description>Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status</description>
    <arm_group_label>Surgery Group</arm_group_label>
    <other_name>SLPCV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Expected Management</intervention_name>
    <description>Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.</description>
    <arm_group_label>Expectant Management Group</arm_group_label>
    <other_name>expectant management (current accepted treatment)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age 16--24 weeks

          -  Sonographic evidence of monochorionicity: single placenta, same gender, absent
             twin-peak sign

          -  Diagnosis of IUGR present in one twin (fetal weight at or below the 10th percentile
             for gestational age)

          -  Persistent absent or reverse-end diastolic flow in the umbilical artery in the SIUGR
             twin

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Patients unwilling to participate in the study, provide consent, or to be followed up

          -  Presence of twin-twin transfusion syndrome (TTTS) defined as a maximum vertical pocket
             (MVP) of ≤2 cm in one sac and MVP of ≥8 cm in the other sac.

          -  Presence of major congenital anomalies (anencephaly, acardia, spina bifida) or
             intracranial findings in either twin: IVH, porencephalic cysts, ventriculomegaly or
             other findings suggestive of brain damage.

          -  Both twins are &lt;10th percentile

          -  Diastolic flow or intermittently absent end-diastolic flow in the umbilical artery in
             the SIUGR twin

          -  Unbalanced chromosomal complement (if known).

          -  Ruptured or detached membranes

          -  Placental abruption

          -  Chorioamnionitis

          -  Triplets

          -  Active labor

          -  Jehovah's witness

          -  Any other patient deemed inappropriate for the study by the principal investigator

          -  Placenta previa
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben A Quintero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://fetalmd.hsc.usf.edu</url>
    <description>USF-TGH Fetal Therapy Center</description>
  </link>
  <reference>
    <citation>Lin CC, Santolaya-Forgas J. Current concepts of fetal growth restriction: part I. Causes, classification, and pathophysiology. Obstet Gynecol. 1998 Dec;92(6):1044-55. Review.</citation>
    <PMID>9840574</PMID>
  </reference>
  <reference>
    <citation>Ananth CV, Vintzileos AM, Shen-Schwarz S, Smulian JC, Lai YL. Standards of birth weight in twin gestations stratified by placental chorionicity. Obstet Gynecol. 1998 Jun;91(6):917-24.</citation>
    <PMID>9610996</PMID>
  </reference>
  <reference>
    <citation>Hamilton EF, Platt RW, Morin L, Usher R, Kramer M. How small is too small in a twin pregnancy? Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):682-5.</citation>
    <PMID>9757971</PMID>
  </reference>
  <reference>
    <citation>Dudley DK, D'Alton ME. Single fetal death in twin gestation. Semin Perinatol. 1986 Jan;10(1):65-72.</citation>
    <PMID>3764450</PMID>
  </reference>
  <reference>
    <citation>Fusi L, Gordon H. Twin pregnancy complicated by single intrauterine death. Problems and outcome with conservative management. Br J Obstet Gynaecol. 1990 Jun;97(6):511-6.</citation>
    <PMID>2198920</PMID>
  </reference>
  <reference>
    <citation>Lin IJ, Chen CH, Wang TM, Fu LS, Chi CS. Infants of twin pregnancies with one twin demise in the uterus: a retrospective study. Acta Paediatr Taiwan. 1999 Mar-Apr;40(2):92-6.</citation>
    <PMID>10910594</PMID>
  </reference>
  <reference>
    <citation>Axt R, Hippach M, Mink D, Hendrik HJ, Ertan AK, Schmidt W. Maternal and neonatal outcome in a monochorionic twin pregnancy complicated by single intrauterine demise. Clin Exp Obstet Gynecol. 1999;26(3-4):155-7.</citation>
    <PMID>10668142</PMID>
  </reference>
  <reference>
    <citation>Petersen IR, Nyholm HC. Multiple pregnancies with single intrauterine demise. Description of twenty-eight pregnancies. Acta Obstet Gynecol Scand. 1999 Mar;78(3):202-6.</citation>
    <PMID>10078581</PMID>
  </reference>
  <reference>
    <citation>Burke MS. Single fetal demise in twin gestation. Clin Obstet Gynecol. 1990 Mar;33(1):69-78. Review.</citation>
    <PMID>2178843</PMID>
  </reference>
  <reference>
    <citation>Saito K, Ohtsu Y, Amano K, Nishijima M. Perinatal outcome and management of single fetal death in twin pregnancy: a case series and review. J Perinat Med. 1999;27(6):473-7.</citation>
    <PMID>10732306</PMID>
  </reference>
  <reference>
    <citation>Nicolini U, Poblete A. Single intrauterine death in monochorionic twin pregnancies. Ultrasound Obstet Gynecol. 1999 Nov;14(5):297-301. Review.</citation>
    <PMID>10623986</PMID>
  </reference>
  <reference>
    <citation>Kilby MD, Govind A, O'Brien PM. Outcome of twin pregnancies complicated by a single intrauterine death: a comparison with viable twin pregnancies. Obstet Gynecol. 1994 Jul;84(1):107-9.</citation>
    <PMID>8008302</PMID>
  </reference>
  <reference>
    <citation>Adegbite AL, Castille S, Ward S, Bajoria R. Neuromorbidity in preterm twins in relation to chorionicity and discordant birth weight. Am J Obstet Gynecol. 2004 Jan;190(1):156-63.</citation>
    <PMID>14749653</PMID>
  </reference>
  <reference>
    <citation>Karsdorp VH, van Vugt JM, van Geijn HP, Kostense PJ, Arduini D, Montenegro N, Todros T. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. Lancet. 1994 Dec 17;344(8938):1664-8.</citation>
    <PMID>7996959</PMID>
  </reference>
  <reference>
    <citation>Valcamonico A, Danti L, Frusca T, Soregaroli M, Zucca S, Abrami F, Tiberti A. Absent end-diastolic velocity in umbilical artery: risk of neonatal morbidity and brain damage. Am J Obstet Gynecol. 1994 Mar;170(3):796-801.</citation>
    <PMID>8141204</PMID>
  </reference>
  <reference>
    <citation>Gratacós E, Carreras E, Becker J, Lewi L, Enríquez G, Perapoch J, Higueras T, Cabero L, Deprest J. Prevalence of neurological damage in monochorionic twins with selective intrauterine growth restriction and intermittent absent or reversed end-diastolic umbilical artery flow. Ultrasound Obstet Gynecol. 2004 Aug;24(2):159-63.</citation>
    <PMID>15287053</PMID>
  </reference>
  <reference>
    <citation>Huber A, Diehl W, Zikulnig L, Bregenzer T, Hackelöer BJ, Hecher K. Perinatal outcome in monochorionic twin pregnancies complicated by amniotic fluid discordance without severe twin-twin transfusion syndrome. Ultrasound Obstet Gynecol. 2006 Jan;27(1):48-52.</citation>
    <PMID>16323150</PMID>
  </reference>
  <reference>
    <citation>De Lia JE, Cruikshank DP, Keye WR Jr. Fetoscopic neodymium:YAG laser occlusion of placental vessels in severe twin-twin transfusion syndrome. Obstet Gynecol. 1990 Jun;75(6):1046-53.</citation>
    <PMID>2342732</PMID>
  </reference>
  <reference>
    <citation>DeLia JE, Cukierski MA, Lundergan DK, Kochenour NK. Neodymium:yttrium-aluminum-garnet laser occlusion of rhesus placental vasculature via fetoscopy. Am J Obstet Gynecol. 1989 Feb;160(2):485-9.</citation>
    <PMID>2916637</PMID>
  </reference>
  <reference>
    <citation>DeLia JE, Rogers JG, Dixon JA. Treatment of placental vasculature with a neodymium-yttrium-aluminum-garnet laser via fetoscopy. Am J Obstet Gynecol. 1985 Apr 15;151(8):1126-7.</citation>
    <PMID>4039109</PMID>
  </reference>
  <reference>
    <citation>Ville Y, Hyett J, Hecher K, Nicolaides K. Preliminary experience with endoscopic laser surgery for severe twin-twin transfusion syndrome. N Engl J Med. 1995 Jan 26;332(4):224-7.</citation>
    <PMID>7808488</PMID>
  </reference>
  <reference>
    <citation>Quintero RA, Morales WJ, Mendoza G, Allen M, Kalter CS, Giannina G, Angel JL. Selective photocoagulation of placental vessels in twin-twin transfusion syndrome: evolution of a surgical technique. Obstet Gynecol Surv. 1998 Dec;53(12 Suppl):S97-103.</citation>
    <PMID>9870237</PMID>
  </reference>
  <reference>
    <citation>Quintero RA, Romero R, Reich H, Gonçalves L, Johnson MP, Carreño C, Evans MI. In utero percutaneous umbilical cord ligation in the management of complicated monochorionic multiple gestations. Ultrasound Obstet Gynecol. 1996 Jul;8(1):16-22.</citation>
    <PMID>8843613</PMID>
  </reference>
  <reference>
    <citation>Lewi L, Gratacos E, Ortibus E, Van Schoubroeck D, Carreras E, Higueras T, Perapoch J, Deprest J. Pregnancy and infant outcome of 80 consecutive cord coagulations in complicated monochorionic multiple pregnancies. Am J Obstet Gynecol. 2006 Mar;194(3):782-9.</citation>
    <PMID>16522413</PMID>
  </reference>
  <reference>
    <citation>Robyr R, Yamamoto M, Ville Y. Selective feticide in complicated monochorionic twin pregnancies using ultrasound-guided bipolar cord coagulation. BJOG. 2005 Oct;112(10):1344-8.</citation>
    <PMID>16167936</PMID>
  </reference>
  <reference>
    <citation>Quintero RA, Bornick PW, Morales WJ, Allen MH. Selective photocoagulation of communicating vessels in the treatment of monochorionic twins with selective growth retardation. Am J Obstet Gynecol. 2001 Sep;185(3):689-96.</citation>
    <PMID>11568799</PMID>
  </reference>
  <reference>
    <citation>Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology. 1991 Oct;181(1):129-33.</citation>
    <PMID>1887021</PMID>
  </reference>
  <reference>
    <citation>Arduini D, Rizzo G, Mancuso S, Romanini C. Short-term effects of maternal oxygen administration on blood flow velocity waveforms in healthy and growth-retarded fetuses. Am J Obstet Gynecol. 1988 Nov;159(5):1077-80.</citation>
    <PMID>3055996</PMID>
  </reference>
  <reference>
    <citation>Martínez JM, Bermúdez C, Becerra C, López J, Morales WJ, Quintero RA. The role of Doppler studies in predicting individual intrauterine fetal demise after laser therapy for twin-twin transfusion syndrome. Ultrasound Obstet Gynecol. 2003 Sep;22(3):246-51.</citation>
    <PMID>12942495</PMID>
  </reference>
  <reference>
    <citation>Quintero RA, Comas C, Bornick PW, Allen MH, Kruger M. Selective versus non-selective laser photocoagulation of placental vessels in twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol. 2000 Sep;16(3):230-6.</citation>
    <PMID>11169288</PMID>
  </reference>
  <reference>
    <citation>Quintero R. Diagnostic and Operative Fetoscopy. New York: The Parthenon Publishing Group, 2002.</citation>
  </reference>
  <reference>
    <citation>Quintero RA, Dickinson JE, Morales WJ, Bornick PW, Bermúdez C, Cincotta R, Chan FY, Allen MH. Stage-based treatment of twin-twin transfusion syndrome. Am J Obstet Gynecol. 2003 May;188(5):1333-40.</citation>
    <PMID>12748508</PMID>
  </reference>
  <reference>
    <citation>Saunders NJ, Snijders RJ, Nicolaides KH. Therapeutic amniocentesis in twin-twin transfusion syndrome appearing in the second trimester of pregnancy. Am J Obstet Gynecol. 1992 Mar;166(3):820-4.</citation>
    <PMID>1550147</PMID>
  </reference>
  <reference>
    <citation>Morales W. Selective photocoagulation of placental vessels in twin-twin transfusion syndrome: outcomes and complications. In: Quintero R, ed. Twin-twin transfusion syndrome. London: Taylor and Francis, Scheduled for publication in 2006.</citation>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <results_first_submitted>September 21, 2012</results_first_submitted>
  <results_first_submitted_qc>November 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2012</results_first_posted>
  <last_update_submitted>February 20, 2013</last_update_submitted>
  <last_update_submitted_qc>February 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intrauterine Growth Retardation in Monochorionic Twins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Surgery Group</title>
          <description>Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.
Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures.</description>
        </group>
        <group group_id="P2">
          <title>Expectant Management Group</title>
          <description>Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">data as of March 2009</participants>
                <participants group_id="P2" count="2">data as of March 2009</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>babies not yet 6 months of age</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Surgery Group</title>
          <description>Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.
Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures.</description>
        </group>
        <group group_id="B2">
          <title>Expectant Management Group</title>
          <description>Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient’s perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>Effects of surgery or expectant management on postnatal neurological morbidity of the AGA baby. The primary comparison will be between SLPCV (selective laser photocoagulation of communicating vessels) and expectant management.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surgery Group</title>
            <description>Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.
Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures.</description>
          </group>
          <group group_id="O2">
            <title>Expectant Management Group</title>
            <description>Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Effects of surgery or expectant management on postnatal neurological morbidity of the AGA baby. The primary comparison will be between SLPCV (selective laser photocoagulation of communicating vessels) and expectant management.</description>
          <units>percentage of AGA babies who survived</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal/Neonatal/Infant Survival of the AGA Fetus 6 Months After Birth, Comparing the SLPCV (Selective Laser Photocoagulation of Communicating Vessels) and Expectant Management Groups.</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Surgery Group</title>
          <description>Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.
Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures.</description>
        </group>
        <group group_id="E2">
          <title>Expectant Management Group</title>
          <description>Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Coordinator</name_or_title>
      <organization>University of South Florida</organization>
      <phone>813-259-8680</phone>
      <email>obgynclinicalresearch@health.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

